Graudins Andis, Wong Kathy Ka Ling
Clinical and Experimental Toxicology Unit, Department of Emergency Medicine, Prince of Wales Hospital, Randwick, NSW, Australia.
J Med Toxicol. 2010 Jun;6(2):85-93. doi: 10.1007/s13181-010-0073-y.
Levosimendan (Levo) increases sensitivity of troponin-C to calcium, thus increasing myocardial contractility. It is also a vascular K+-ATP channel agonist producing peripheral vasodilation. Previous research with levosimendan revealed an increase in cardiac output (CO) but not blood pressure (BP) in experimental verapamil poisoning. Levosimendan's K+-channel agonist properties may augment verapamil's vasodilatory effects. 4-Aminopyridine (4-AP) is a K+-channel antagonist. It has successfully reversed hypotension in experimental verapamil poisoning. We hypothesized that coadministration of these agents may improve BP and CO in verapamil poisoning. Anesthetized, ventilated, and canulated male Wistar rats were poisoned with verapamil. Animals received one of six treatments, which are as follows: (1) n-saline infusion (control), (2) Levo 6.25 μg/kg loading dose and 36 μg/kg/h infusion, (3) 4-AP 2 mg/kg loading dose and infusion (4-AP), (4) Levo+4-AP, (5) CaCl₂ loading dose and infusion, and (6) Levo+CaCl(2). Hemodynamic parameters were recorded for 60 min. Outcome measures were changes in CO, BP, and heart rate (HR) compared to control. All groups had similar pretoxicity and peak toxicity CO (50% of pretoxicity value), BP (50% or pretoxicity value), and HR. Control group CO, BP, and HR progressively dropped during the verapamil infusion. Levosimendan produced a statistically significant improvement in CO (75% of pretoxicity level) but not BP in comparison to control. 4-AP produced a significant improvement in CO (110% of pretoxicity) and BP (78% of pretoxicity). Levo+4-AP and Levo+CaCl₂ groups improved CO (100% of pretoxicity) and BP (77% and 50% of pretoxicity, respectively), but there was no additive increase in CO or BP in animals compared to 4-AP or CaCl₂ alone. Levosimendan moderately improved CO but not BP in verapamil poisoning. The hypotensive effects of levosimendan were not overcome by coadministration of either 4-AP or CaCl₂. Levosimendan may not be an appropriate agent to use in the treatment of verapamil poisoning.
左西孟旦可增加肌钙蛋白C对钙的敏感性,从而增强心肌收缩力。它还是一种血管钾离子ATP通道激动剂,可引起外周血管舒张。先前关于左西孟旦的研究表明,在实验性维拉帕米中毒中,心输出量(CO)增加,但血压(BP)未升高。左西孟旦的钾离子通道激动剂特性可能会增强维拉帕米的血管舒张作用。4-氨基吡啶(4-AP)是一种钾离子通道拮抗剂。它已成功逆转实验性维拉帕米中毒导致的低血压。我们推测,联合使用这些药物可能会改善维拉帕米中毒时的血压和心输出量。将麻醉、通气并插管的雄性Wistar大鼠用维拉帕米中毒。动物接受以下六种治疗之一:(1)生理盐水输注(对照),(2)左西孟旦6.25μg/kg负荷剂量和36μg/kg/h输注,(3)4-AP 2mg/kg负荷剂量和输注(4-AP),(4)左西孟旦+4-AP,(5)氯化钙负荷剂量和输注,以及(6)左西孟旦+氯化钙。记录血流动力学参数60分钟。与对照相比,观察指标为心输出量、血压和心率(HR)的变化。所有组在中毒前和中毒峰值时的心输出量(中毒前值的50%)、血压(中毒前值的50%)和心率相似。对照组的心输出量、血压和心率在维拉帕米输注期间逐渐下降。与对照相比,左西孟旦使心输出量有统计学意义的改善(中毒前水平的75%),但血压未改善。4-AP使心输出量(中毒前的110%)和血压(中毒前的78%)有显著改善。左西孟旦+4-AP组和左西孟旦+氯化钙组的心输出量(中毒前的100%)和血压(分别为中毒前的77%和50%)有所改善,但与单独使用4-AP或氯化钙相比,动物的心输出量或血压没有额外增加。在维拉帕米中毒中,左西孟旦适度改善了心输出量,但未改善血压。联合使用4-AP或氯化钙均未克服左西孟旦的降压作用。左西孟旦可能不是治疗维拉帕米中毒的合适药物。